• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Expanding Medline Sinclair Partnership in Canada Strengthen DENTSPLY SIRONA's (XRAY) Digital Dentistry Edge?

    Simply Wall St·07/29/2026 02:26:39
    Listen to the news
    • DENTSPLY SIRONA Inc. recently announced it will expand its long-standing relationship with Medline Sinclair, enabling the distributor to offer its full technology portfolio across Canada from September 1, 2026, building on a prior focus on consumables.
    • This move broadens access to DENTSPLY SIRONA’s digital dentistry solutions by tapping Medline Sinclair’s coast-to-coast sales, service, and technical support network in the Canadian dental market.
    • We’ll now examine how expanding access to DENTSPLY SIRONA’s digital dentistry portfolio through Medline Sinclair’s national network could influence its investment narrative.

    Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

    DENTSPLY SIRONA Investment Narrative Recap

    To own DENTSPLY SIRONA, you need to believe its digital dentistry ecosystem can eventually offset recent revenue pressure, impairments, and leadership turnover. The Medline Sinclair expansion looks directionally helpful for near term growth efforts, but it does not directly address the most immediate risks around weak sales in key categories and tariff driven margin pressure, which remain central uncertainties for the story today.

    The Medline Sinclair deal also follows expanded U.S. distribution partnerships with Nashville Dental and Benco Dental, which extend access to CEREC, Primescan, imaging, and DS Core across larger territories. Together, these moves point to a broad push to widen the reach of DENTSPLY SIRONA’s technology portfolio. How effectively these partnerships translate into higher utilization and improved profitability will likely be a key test of the current return to growth plan.

    Yet, beneath this expanded distribution story, there is another risk investors should be aware of...

    Read the full narrative on DENTSPLY SIRONA (it's free!)

    DENTSPLY SIRONA's narrative projects $3.8 billion revenue and $189.7 million earnings by 2029. This requires revenue to remain fairly flat each year and a roughly $818 million earnings increase from -$628.0 million today.

    Uncover how DENTSPLY SIRONA's forecasts yield a $13.40 fair value, in line with its current price.

    Exploring Other Perspectives

    XRAY 1-Year Stock Price Chart
    XRAY 1-Year Stock Price Chart

    While the Medline Sinclair expansion highlights upside potential in digital workflows, the most bearish analysts were assuming flat revenue near US$3.7 billion and only US$95.9 million in earnings by 2029, so you should recognize how different your view might be from theirs and consider how this new distribution push could reshape those expectations.

    Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth over 3x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

    Looking For Alternative Opportunities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.